브리스톨 마이어스 스퀴브 (BMY)

개요 뉴스 가격 이력 옵션 체인 Financials BMY 왜 하락? 토론 예측 주식 분할 배당 이력

왜 Bristol-Myers Squibb Co. (BMY) 주가가 하락하고 있습니까?

2024-04-25 거래 세션 동안 Bristol-Myers Squibb Co.(BMY) 주식이 8.51% 하락한 것을 확인했습니다. 이는 정상적인 변동성이나 다양한 내부 및 외부 요인에 의한 것일 수 있지만, 상황을 적극적으로 모니터링하고 있으며 최대한 빨리 적시에 업데이트를 제공하도록 하겠습니다!

2023-11-20:

Bristol-Myers Squibb Co. Stock (BMY) dropped by 3.82% from $50.84 to $48.90 in the trading on Monday November 20, 2023. The reasons why BMY stock down today is due to the delay in FDA approval. The ODAC will review data for its Abecma gene therapy based on results from the pivotal Phase 3 KarMMa-3 study. The FDA has not yet confirmed the date of the ODAC meeting and has informed the companies that a decision on the application will not be made by the Prescription Drug User Fee Act (PDUFA) target action date of December 16, 2023.

2023-10-26:

Bristol-Myers Squibb Company Stock (BMY) dropped by 6.43% from $56.61 to $52.97 in the trading on Thursday October 26, 2023. The reason why BMY stock down today include:

Decreased revenues: Bristol's sales fell 2% but were ahead of the Street's $10.96 billion projection. Several of Bristol Myers' big-name drugs missed expectations. Revenue from cancer drug Opdivo grew 11% to $2.28 billion, but narrowly lagged forecasts for $2.32 billion. Eliquis sales edged up 2% to $2.71 billion, below projections for $2.84 billion. Revlimid sales also plummeted 41% to $1.43 billion.
Several difficulties: Bristol Myers has faced slower-than-expected adoption for cardiomyopathy drug Camzyos and insurance headwinds for Sotyktu. Bristol Myers is already struggling with generics taking a bite out of one of its cancer heavyweights.
Concerns about milestone achieving: Previously, Bristol Myers expected new products like anemia treatment Reblozyl, psoriasis medicine Sotyktu and multiple sclerosis drug Zeposia to generate $10 billion to $13 billion in sales in 2025. Now, the company doesn't expect to reach the low end of that until 2026.